You may report side effects to FDA at 1-800-FDA-1088. ZIMHI is designed to be administered in the muscle (intramuscular) or under the skin (subcutaneous) using a single-dose, prefilled syringe . ADMP - Adamis Pharmaceuticals Corporation - BioPharmCatalyst FDA Rejects High-Dose Naloxone Shot for Opioid Overdose FDA approves naloxone injection to counteract opioid overdoses SAN DIEGO, June 09, 2021 (GLOBE NEWSWIRE) — Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's resubmitted New Drug Application (NDA) for ZIMHI™, which is its higher naloxone injection product candidate for the treatment of opioid overdose. Adamis Pharmaceuticals Describes Planned Response to ZIMHI Adamis Receives FDA Approval for ZIMHI | ADMP Stock News ZIMHI is a high-dose naloxone injection product FDA-approved for use in the treatment of opioid overdose. SAN DIEGO, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced that the U.S. Food and Drug Administration (FDA) has approved Adamis' ZIMHI™ (naloxone HCL Injection, USP) 5 mg/0.5 mL product. Adamis Pharmaceuticals Corporation. Adamis Pharmaceuticals (ADMP) Receives CRL from the FDA Regarding ZIMHI Adamis Pharmaceuticals Corporation announced the FDA has approved ZIMHI 5 mg/0.5 mL, a high-dose naloxone injection for use in the treatment of opioid overdose.The company is preparing for the full commercial launch of ZIMHI in the first quarter of 2022.
